[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

BR112012016129A2 - composto, composição, e, métodos para inibir a atividade de c-met, e para tratar câncer - Google Patents

composto, composição, e, métodos para inibir a atividade de c-met, e para tratar câncer

Info

Publication number
BR112012016129A2
BR112012016129A2 BR112012016129A BR112012016129A BR112012016129A2 BR 112012016129 A2 BR112012016129 A2 BR 112012016129A2 BR 112012016129 A BR112012016129 A BR 112012016129A BR 112012016129 A BR112012016129 A BR 112012016129A BR 112012016129 A2 BR112012016129 A2 BR 112012016129A2
Authority
BR
Brazil
Prior art keywords
methods
inhibiting
compound
composition
treating cancer
Prior art date
Application number
BR112012016129A
Other languages
English (en)
Other versions
BR112012016129B1 (pt
Inventor
Guangxiu Dai
Hong Jia
Wei-Guo Su
Original Assignee
Hutchison Medipharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44226181&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112012016129(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hutchison Medipharma Ltd filed Critical Hutchison Medipharma Ltd
Publication of BR112012016129A2 publication Critical patent/BR112012016129A2/pt
Publication of BR112012016129B1 publication Critical patent/BR112012016129B1/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyridine Compounds (AREA)

Abstract

composto, composição, e, métodos para inibir a atividade de c-met, e para tratar câncer. são fornecidas certas triazolopiridinas e triazolopirizinas, composições das mesmas e métodos de uso para as mesmas.
BR112012016129-6A 2009-12-31 2010-12-30 composto, composição e uso dos ditos compostos BR112012016129B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2009076321 2009-12-31
CNPCT/CN2009/076321 2009-12-31
PCT/CN2010/080499 WO2011079804A1 (en) 2009-12-31 2010-12-30 Certain triazolopyridines and triazolopyrazines, compositions thereof and methods of use therefor

Publications (2)

Publication Number Publication Date
BR112012016129A2 true BR112012016129A2 (pt) 2016-05-31
BR112012016129B1 BR112012016129B1 (pt) 2020-11-03

Family

ID=44226181

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112012016129-6A BR112012016129B1 (pt) 2009-12-31 2010-12-30 composto, composição e uso dos ditos compostos

Country Status (38)

Country Link
US (8) US8987269B2 (pt)
EP (5) EP3795573B1 (pt)
JP (5) JP5337313B2 (pt)
KR (3) KR101434766B1 (pt)
CN (3) CN106117248B (pt)
AU (2) AU2010338712B2 (pt)
BR (1) BR112012016129B1 (pt)
CA (1) CA2785749C (pt)
CL (1) CL2012001752A1 (pt)
CO (1) CO6612235A2 (pt)
CU (1) CU24167B1 (pt)
CY (2) CY1118250T1 (pt)
DK (3) DK3795573T3 (pt)
DO (1) DOP2012000188A (pt)
EA (2) EA025466B1 (pt)
EC (1) ECSP12012011A (pt)
ES (4) ES2927146T3 (pt)
GT (1) GT201200220A (pt)
HK (2) HK1194071A1 (pt)
HR (3) HRP20221090T1 (pt)
HU (3) HUE025504T2 (pt)
IL (2) IL220433B (pt)
LT (1) LT3795573T (pt)
ME (1) ME02211B (pt)
MX (1) MX336996B (pt)
MY (1) MY179933A (pt)
NI (1) NI201200118A (pt)
NZ (1) NZ601128A (pt)
PE (3) PE20130375A1 (pt)
PL (3) PL2719699T3 (pt)
PT (3) PT3511330T (pt)
RS (3) RS63612B1 (pt)
SG (1) SG181781A1 (pt)
SI (2) SI3511330T1 (pt)
SM (1) SMT201500213B (pt)
UA (1) UA107822C2 (pt)
WO (1) WO2011079804A1 (pt)
ZA (1) ZA201205730B (pt)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20221090T1 (hr) * 2009-12-31 2022-11-25 Hutchison Medipharma Limited Određeni triazolopirazini, njihovi pripravci i postupci njihove upotrebe
EP2571878B1 (en) 2010-05-17 2018-10-17 Incozen Therapeutics Pvt. Ltd. Novel 3,5-disubstitued-3h-imidazo[4,5-b]pyridine and 3,5- disubstitued -3h-[1,2,3]triazolo[4,5-b]pyridine compounds as modulators of protein kinases
CN103030654A (zh) * 2011-10-09 2013-04-10 济南赛文医药技术有限公司 一种小分子c-Met蛋白激酶抑制剂
CN102516046A (zh) * 2011-11-22 2012-06-27 太仓市运通化工厂 一种2-溴丙醛的合成方法
CN107082779A (zh) * 2012-03-30 2017-08-22 理森制药股份公司 作为c‑met 蛋白激酶调节剂的新化合物
CA2776178A1 (en) 2012-04-05 2013-10-05 Hydro-Quebec Ionic compounds
KR101745741B1 (ko) 2012-08-13 2017-06-12 한국화학연구원 신규한 트리아졸로 피라진 유도체 및 그의 용도
BR112015016580A2 (pt) 2013-01-11 2017-07-11 Fujifilm Corp composto heterocíclico contendo nitrogênio ou sal deste
KR101645112B1 (ko) 2013-03-06 2016-08-02 아스트라제네카 아베 표피 성장 인자 수용체의 활성화 돌연변이체 형태의 퀴나졸린 억제제
CN103265468A (zh) * 2013-06-17 2013-08-28 连云港盛和生物科技有限公司 一种2,4-二甲基-3-吡咯甲酸乙酯的合成方法
EP2818471A1 (en) * 2013-06-27 2014-12-31 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Nitrogen bicyclic compounds as inhibitors for Scyl1 and Grk5
CN104703988B (zh) * 2013-09-30 2017-04-12 韩国化学研究院 新的三唑并吡嗪衍生物及其用途
HUE037579T2 (hu) * 2013-12-26 2018-09-28 Ignyta Inc Pirazolo[1,5-a]piridin-származékok és módszerek alkalmazásukra
JP2016048495A (ja) * 2014-08-28 2016-04-07 京セラ株式会社 携帯端末、レコメンドプログラム、レコメンドシステムおよびレコメンド方法
WO2017035401A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Amide compounds for treatment of immune and inflammatory disorders
EP3340983B1 (en) 2015-08-26 2023-10-04 Achillion Pharmaceuticals, Inc. Aryl, heteroaryl, and heterocyclic compounds for treatment of immune and inflammatory disorders
WO2017035405A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Amino compounds for treatment of immune and inflammatory disorders
ES2877799T3 (es) * 2015-12-31 2021-11-17 Shanghai Pharmaceuticals Holding Co Ltd Sal de derivado de quinolina, formas polimórficas de la misma, métodos de preparación de la misma, composición y aplicaciones
GB201616116D0 (en) 2016-09-22 2016-11-09 Astrazeneca Ab Use of c-Met inhibitors to treat cancers harbouring MET mutations
KR20180092096A (ko) * 2017-02-08 2018-08-17 에이비온 주식회사 트리아졸로 피라진 유도체의 신규한 다형체 및 이의 제조 방법
EP3589628A4 (en) 2017-03-01 2021-03-31 Achillion Pharmaceuticals, Inc. ARYL, HETEROARYL AND HETEROCYCLIC COMPOUNDS FOR TREATMENT OF MEDICAL DISEASES
WO2018160891A1 (en) 2017-03-01 2018-09-07 Achillion Pharmaceutical, Inc. Pharmaceutical compounds for treatment of medical disorders
EP3589287B1 (en) 2017-03-01 2022-09-14 Achillion Pharmaceuticals, Inc. Macrocyclic compounds for treatment of medical disorders
CN108570053A (zh) * 2017-03-13 2018-09-25 中国科学院上海药物研究所 五元并六元杂环化合物、制备方法、中间体、组合和应用
KR101924801B1 (ko) 2017-08-16 2018-12-04 한국원자력의학원 트리아졸로피리딘계 유도체를 유효성분으로 함유하는 암 예방 또는 치료용 조성물
HU231333B1 (hu) 2018-07-13 2023-01-28 Richter Gedeon Nyrt Spirokromán származékok
JP7443375B2 (ja) 2018-09-06 2024-03-05 アキリオン ファーマシューティカルズ， インコーポレーテッド 医学的障害の治療のための大環状化合物
CA3111810A1 (en) 2018-09-06 2020-03-12 Achillion Pharmaceuticals, Inc. Morphic forms of dancopan
EP3849977B1 (en) 2018-09-11 2023-07-19 Astrazeneca AB Improved method for the manufacture of 3-[(1s)-1-imidazo[1,2-a]pyridin-6-ylethyl]-5-(1-methylpyrazol-4-yl)triazolo[4,5-b]pyrazine and polymorphic forms thereof
AU2019346464A1 (en) 2018-09-25 2021-04-08 Achillion Pharmaceuticals, Inc. Morphic forms of complement factor D inhibitors
EP3873905A4 (en) * 2018-10-30 2022-08-17 Repare Therapeutics Inc. COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND METHODS OF MAKING COMPOUNDS AND THEIR USE AS ATR KINASE INHIBITORS
CN113412112B (zh) 2018-12-14 2024-06-11 贝达医药公司 作为c-MET抑制剂的有机磷取代化合物及其治疗用途
EP4003993A4 (en) * 2019-07-22 2023-01-18 Repare Therapeutics Inc. SUBSTITUTED 2-MORPHOLINOPYRIDE DERIVATIVES AS ATR KINASE INHIBITORS
EP4107166A4 (en) * 2020-02-20 2024-06-26 Achillion Pharmaceuticals, Inc. HETEROARYL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT FACTOR D-MEDIATED DISORDERS
WO2021229605A1 (en) * 2020-05-14 2021-11-18 Dr. Reddy's Laboratories Limited Process for preparation of savolitinib and its intermediates
IL301146A (en) * 2020-09-28 2023-05-01 Codexis Inc Engineered biocatalysts and methods for the synthesis of chiral amines
CN117222634A (zh) * 2020-12-16 2023-12-12 艾福姆德尤股份有限公司 用于治疗与sting活性有关的疾病的化合物和组合物
KR102659095B1 (ko) 2021-01-08 2024-04-19 에이비온 주식회사 트리아졸로피라진 유도체 화합물을 유효성분으로 하는 약학적 조성물의 태블릿정의 제조방법
CN113278019A (zh) * 2021-05-31 2021-08-20 河南偶联生物科技有限公司 一种咪唑并[1,2-a]吡啶类化合物的合成方法
WO2023205722A1 (en) * 2022-04-20 2023-10-26 Engrail Therapeutics, Inc. Gabaa receptor modulator salts, particles, and uses thereof
WO2024008929A1 (en) 2022-07-08 2024-01-11 Astrazeneca Ab Epidermal growth factor receptor tyrosine kinase inhibitors in combination with hgf-receptor inhibitors for the treatment of cancer
WO2024026410A2 (en) * 2022-07-29 2024-02-01 Baylor College Of Medicine Neurotrophic receptor tyrosine kinase (ntrk) inhibitors and methods using same
CN115611802B (zh) * 2022-12-02 2023-03-14 北京迪泰医药科技有限公司 一种3-乙酰基-2-氯吡啶的合成方法
WO2024148089A1 (en) * 2023-01-04 2024-07-11 Blueprint Medicines Corporation Cdk2 inhibitors
GB202300923D0 (en) 2023-01-20 2023-03-08 Macfarlan Smith Ltd Novel polymorphic forms of savolitinib

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3989816A (en) 1975-06-19 1976-11-02 Nelson Research & Development Company Vehicle composition containing 1-substituted azacycloheptan-2-ones
US4444762A (en) 1980-04-04 1984-04-24 Nelson Research & Development Company Vehicle composition containing 1-substituted azacyclopentan-2-ones
US5977134A (en) * 1996-12-05 1999-11-02 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
WO2004092177A1 (en) 2003-04-09 2004-10-28 Biogen Idec Ma Inc. Triazolopyrazines and methods of making and using the same
US6979505B2 (en) * 2003-06-09 2005-12-27 Utc Fuel Cells, Llc Method and apparatus for removal of contaminants from a hydrogen processor feed stream, as in a fuel cell power plant
US7122548B2 (en) 2003-07-02 2006-10-17 Sugen, Inc. Triazolotriazine compounds and uses thereof
EP1643836A4 (en) * 2003-07-02 2006-12-06 Sugen Inc ARYLMETHYL TRIAZOLO AND IMIDAZOPYRAZINE C-MET INHIBITORS
US20050070542A1 (en) 2003-09-03 2005-03-31 Hodgetts Kevin J. 5-Aryl-pyrazolo[4,3-d]pyrimidines, pyridines, and pyrazines and related compounds
KR20070053237A (ko) 2004-07-27 2007-05-23 에스지엑스 파마슈티컬스, 인코포레이티드 피롤로-피리딘 키나제 조절제
MX2007002050A (es) 2004-08-18 2007-03-29 Pharmacia & Upjohn Co Llc Compuestos de triazolopiridina.
CN101119996A (zh) * 2005-02-16 2008-02-06 阿斯利康(瑞典)有限公司 化学化合物
EP1853602B1 (en) * 2005-02-16 2010-07-14 AstraZeneca AB Chemical compounds
US7728017B2 (en) 2005-11-30 2010-06-01 Vertex Pharmaceuticals Incorporated Inhibitors of c-Met and uses thereof
PT1966214T (pt) * 2005-12-21 2017-02-03 Janssen Pharmaceutica Nv Triazolpiridazinas como moduladores de tirosina quinase
NL2000613C2 (nl) * 2006-05-11 2007-11-20 Pfizer Prod Inc Triazoolpyrazinederivaten.
CA2651979A1 (en) * 2006-05-30 2007-12-06 Pfizer Products Inc. Triazolopyridazine derivatives
US8217177B2 (en) 2006-07-14 2012-07-10 Amgen Inc. Fused heterocyclic derivatives and methods of use
PE20121506A1 (es) 2006-07-14 2012-11-26 Amgen Inc Compuestos triazolopiridinas como inhibidores de c-met
EP2057164A1 (en) 2006-08-07 2009-05-13 Incyte Corporation Triazolotriazines as kinase inhibitors
WO2008036272A1 (en) 2006-09-18 2008-03-27 Vertex Pharmaceuticals Incorporated HETEROCYCLIC INHIBITORS OF c-MET AND USES THEREOF
US8507489B2 (en) 2006-10-23 2013-08-13 Sgx Pharmaceuticals, Inc. Bicyclic triazoles as protein kinase modulators
ES2393132T3 (es) * 2006-10-23 2012-12-18 Sgx Pharmaceuticals, Inc. Moduoladores de proteína quinasa de triazolopiridazina
DK2497470T3 (en) 2006-11-22 2015-12-07 Incyte Holdings Corp Imidazotriaziner and imidazopyrimidines as kinase inhibitors
US8242280B2 (en) 2007-04-10 2012-08-14 Sgx Pharmaceuticals, Inc. Fused ring heterocycle kinase modulators
US8148369B2 (en) 2007-05-10 2012-04-03 Janssen Pharmaceutica Nv Fused pyrazine compounds useful for the treatment of degenerative and inflammatory diseases
PA8792501A1 (es) 2007-08-09 2009-04-23 Sanofi Aventis Nuevos derivados de 6-triazolopiridacina-sulfanil benzotiazol y bencimidazol,su procedimiento de preparación,su aplicación como medicamentos,composiciones farmacéuticas y nueva utilización principalmente como inhibidores de met.
CA2717034A1 (en) 2008-02-28 2009-09-03 Pascal Furet Imidazo[1,2-b]pyridazine derivatives for the treatment of c-met tyrosine kinase mediated disease
ATE540038T1 (de) 2008-05-22 2012-01-15 Amgen Inc Heterocyclen als proteinkinaseinhibitoren
DE102008037790A1 (de) 2008-08-14 2010-02-18 Merck Patent Gmbh Bicyclische Triazolderivate
UY32049A (es) 2008-08-14 2010-03-26 Takeda Pharmaceutical Inhibidores de cmet
US8497368B2 (en) * 2009-08-12 2013-07-30 Novartis Ag Heterocyclic hydrazone compounds
EA201200318A1 (ru) * 2009-08-20 2012-09-28 Новартис Аг Гетероциклические оксимы
HRP20221090T1 (hr) * 2009-12-31 2022-11-25 Hutchison Medipharma Limited Određeni triazolopirazini, njihovi pripravci i postupci njihove upotrebe
EP2571878B1 (en) 2010-05-17 2018-10-17 Incozen Therapeutics Pvt. Ltd. Novel 3,5-disubstitued-3h-imidazo[4,5-b]pyridine and 3,5- disubstitued -3h-[1,2,3]triazolo[4,5-b]pyridine compounds as modulators of protein kinases

Also Published As

Publication number Publication date
EP2966075B1 (en) 2019-02-27
US20210154192A1 (en) 2021-05-27
MX336996B (es) 2016-02-09
HK1194071A1 (en) 2014-10-10
RS61281B1 (sr) 2021-02-26
US9956218B2 (en) 2018-05-01
UA107822C2 (en) 2015-02-25
HRP20221090T1 (hr) 2022-11-25
CN102906092A (zh) 2013-01-30
KR20170098324A (ko) 2017-08-29
CU20120101A7 (es) 2012-10-15
CA2785749A1 (en) 2011-07-07
JP2016155848A (ja) 2016-09-01
EP3511330A1 (en) 2019-07-17
HUE052828T2 (hu) 2021-05-28
US8987269B2 (en) 2015-03-24
ZA201205730B (en) 2016-01-27
CN106117248A (zh) 2016-11-16
US20120264739A1 (en) 2012-10-18
BR112012016129B1 (pt) 2020-11-03
ME02211B (me) 2016-02-20
HRP20150952T1 (hr) 2015-10-09
CY1118250T1 (el) 2017-06-28
HRP20202017T1 (hr) 2021-02-19
US10512645B2 (en) 2019-12-24
PL3511330T3 (pl) 2021-04-19
AU2015203480A1 (en) 2015-07-16
CO6612235A2 (es) 2013-02-01
US11896592B2 (en) 2024-02-13
MY179933A (en) 2020-11-19
EP3795573A1 (en) 2021-03-24
DK3511330T3 (da) 2020-12-21
ES2726152T3 (es) 2019-10-02
JP2019108345A (ja) 2019-07-04
PE20160588A1 (es) 2016-07-09
US8507487B2 (en) 2013-08-13
CY1123777T1 (el) 2022-03-24
PT2719699E (pt) 2015-09-30
AU2015203480B2 (en) 2017-10-26
PE20130375A1 (es) 2013-04-10
EP2519524A4 (en) 2013-07-03
ES2927146T3 (es) 2022-11-02
ES2546635T3 (es) 2015-09-25
RS54217B1 (en) 2015-12-31
IL239997A0 (en) 2015-08-31
CU24167B1 (es) 2016-03-31
PT3795573T (pt) 2022-09-15
PL3795573T3 (pl) 2022-11-21
KR101771299B1 (ko) 2017-08-24
JP6194046B2 (ja) 2017-09-06
JP6647434B2 (ja) 2020-02-14
EA025466B1 (ru) 2016-12-30
SI2719699T1 (sl) 2015-12-31
JP2013209418A (ja) 2013-10-10
MX2012007756A (es) 2012-11-06
KR20140059307A (ko) 2014-05-15
NI201200118A (es) 2013-01-24
PE20211094A1 (es) 2021-06-14
PL2719699T3 (pl) 2016-01-29
AU2010338712A1 (en) 2012-07-12
HUE059696T2 (hu) 2022-12-28
HK1216880A1 (zh) 2016-12-09
EP2966075A1 (en) 2016-01-13
US20200179377A1 (en) 2020-06-11
US20180263977A1 (en) 2018-09-20
PT3511330T (pt) 2020-12-24
CL2012001752A1 (es) 2013-01-25
RS63612B1 (sr) 2022-10-31
CN106432225A (zh) 2017-02-22
JP2018009004A (ja) 2018-01-18
JP2013516393A (ja) 2013-05-13
JP6486999B2 (ja) 2019-03-20
LT3795573T (lt) 2022-11-10
KR20120125261A (ko) 2012-11-14
EP2719699B1 (en) 2015-07-08
DK3795573T3 (da) 2022-09-19
US20170027934A1 (en) 2017-02-02
IL239997A (en) 2017-11-30
CN102906092B (zh) 2016-08-03
EA030141B1 (ru) 2018-06-29
ECSP12012011A (es) 2012-10-30
AU2010338712B2 (en) 2015-04-02
CN106117248B (zh) 2019-01-22
US10946014B2 (en) 2021-03-16
EA201691461A1 (ru) 2017-01-30
US20150368271A1 (en) 2015-12-24
EP2719699A1 (en) 2014-04-16
NZ601128A (en) 2014-12-24
DOP2012000188A (es) 2012-12-31
ES2840454T3 (es) 2021-07-06
EP3511330B1 (en) 2020-09-30
KR101434766B1 (ko) 2014-08-26
SMT201500213B (it) 2015-10-30
US20120245178A1 (en) 2012-09-27
WO2011079804A1 (en) 2011-07-07
EA201200951A1 (ru) 2013-09-30
US20240139182A1 (en) 2024-05-02
SG181781A1 (en) 2012-07-30
DK2719699T3 (en) 2015-08-24
SI3511330T1 (sl) 2021-01-29
HUE025504T2 (en) 2016-02-29
EP2519524A1 (en) 2012-11-07
JP5337313B2 (ja) 2013-11-06
CA2785749C (en) 2017-11-28
CN106432225B (zh) 2019-02-19
EP3795573B1 (en) 2022-07-06
KR101905350B1 (ko) 2018-11-30
GT201200220A (es) 2014-12-22
IL220433B (en) 2018-01-31

Similar Documents

Publication Publication Date Title
BR112012016129A2 (pt) composto, composição, e, métodos para inibir a atividade de c-met, e para tratar câncer
CO6620055A2 (es) Ciertas amino-pirimidinas, composiciones de las mismas y métodos para el uso de los mismos
EA201492223A1 (ru) Новые диазаспироциклоалканы и азаспироциклоалканы
UA111161C2 (uk) Похідна фталазинонкетону, спосіб її одержання та її фармацевтичне застосування
CL2012002189A1 (es) Compuestos derivados de pirrolidina-2-carboxamidas sustituidas; inhibidores de la interaccion mdm2-p53; composicion farmaceutica; y su uso para el tratamiento del cancer, en particular de tumores solidos.
BR112014021531A8 (pt) composto, composição farmacêutica e usos dos mesmos
CO6630154A2 (es) Ciertas amino-piridazinas, composiciones de las mismas y métodos de uso de los mimos
UY35257A (es) Picolinamidas macrocíclicas como fungicidas, composiciones y metodos para el control de enfermedades vegetales
EA201171367A1 (ru) Винилиндазолильные соединения
CO6321189A2 (es) Compuestos de tiazol y oxazol de bencen-sulfonamida
PH12015500263A1 (en) New bicyclic derivatives
CL2009000448A1 (es) Compuestos derivados de 3-sulfonilamino-n-(1h-pirazolo-[3,4-b]piridin-5il)benzamida; procesos de preparacion; compuestos intermediarios; composicion farmaceutica; y uso para el tratamiento del cancer, tal como sarcoma, carcinoma, adenoma, entre otros.
AR091837A1 (es) Compuestos para inmunoterapia dirigida
CO6321282A2 (es) Derivados de piperidinilindol como inhibidores de aldosterona sintasa
BR112012022879A2 (pt) composto, composição farmacêutica, uso do composto e método de tratamento
MX2014012477A (es) Inhibidores pirrolopirazona de tanquirasa.
EA201490846A1 (ru) Новые производные арилхинолина
EA201590887A1 (ru) Композиция
UA111744C2 (uk) ЗАМІЩЕНІ ПІРИДОПІРАЗИНИ ЯК ІНГІБІТОРИ Syk
BR112013009166A2 (pt) heteroarilas e uso das mesmas.
MX2014014832A (es) Pirrolopirimidona y pirrolopiridona, inhibidores de tanquirasa.
CR20120362A (es) Ciertas triazolopiridinas y triazolopirazinas, composiciones de estas y sus métodos de empleo
BR112012022337A2 (pt) composição e respectivos método de preparação e uso de quantidade eficaz
ECSP11011217A (es) Microbiocidas nuevos.
BR112012019866A8 (pt) Composto, uso do mesmo, composição farmacêutica, e, processo para preparar um composto

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06T Formal requirements before examination [chapter 6.20 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 30/12/2010, OBSERVADAS AS CONDICOES LEGAIS.